Table 2.
Survival outcome random-effects meta-analysis summary table.
| Topic | No. of studies | Total patients | Median follow-up range (Median) (months) | No. (%) of T3/T4 disease patients | Heterogeneity test | Outcome (95 % confidence interval) |
|---|---|---|---|---|---|---|
| I2 | ||||||
| Meta-analysis for primary NPC patients | ||||||
| 1-year OS rates | 6 | 287 | 19–40 (28.5) | N/A a | 2 % | 96 % (92 %-98 %) |
| 2-year OS rates | 7 | 327 | 19–40 (25) | N/A a | 62 % | 93 % (83 %-97 %) |
| 3-year OS rates | 4 | 181 | 19–40 (32) | N/A a | 80 % | 90 % (73 %-97 %) |
| 5-year OS rates | 3 | 98 | 19–40 (32) | N/A a | 56 % | 73 % (52 %-87 %) |
| 1-year PFS rates | 3 | 143 | 14–24 (19) | N/A a | 63 % | 94 % (83 %-98 %) |
| 2-year PFS rates | 3 | 135 | 19–25 (24) | 40 (30 %)/41 (30 %) | 73 % | 91 % (75 %-97 %) |
| 1-year LC rates | 3 | 153 | 32–40 (32) | N/A a | 56 % | 96 % (83 %-99 %) |
| 2-year LC rates | 5 | 220 | 24–40 (32) | N/A a | 56 % | 91 % (82 %-96 %) |
| 3-year LC rates | 3 | 153 | 32–40 (32) | N/A a | 86 % | 89 % (64 %-98 %) |
| 5-year LC rates | 2 | 84 | 32–40 (36) | N/A a | 90 % | 75 % (21 %-97 %) |
| Sensitivity analysis on OS rates by excluding studies with patients having nasopharyngeal papillary adenocarcinoma, and salivary gland-type carcinomas of the nasopharynx | ||||||
| 1-year OS rates | 5 | 228 | 19–40 (25) | N/A a | 0 % | 98 % (95 %-99 %) |
| 2-year OS rates | 6 | 268 | 19–40 (24.5) | N/A a | 68 % | 94 % (84 %-98 %) |
| 3-year OS rates | 3 | 122 | 19–40 (32) | N/A a | 0 % | 94 % (88 %-97 %) |
Note: aUnable to extract data from some studies.
Abbreviations: LC, local control; N/A, not applicable; OS, overall survival; PFS, progression-free survival.